By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – As Illumina shareholders prepare for a vote that could determine the future of Roche's hostile bid for the San Diego company, an investment analyst today said that Roche is unlikely to make any headway in getting a deal done and only has a couple of other options.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.